Stockreport

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

Fortress Biotech, Inc.  (FBIO) 
Last fortress biotech, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: fortressbiotech.com
PDF Nine of 10 cardiac patients on CAEL-101 showed improvement in global longitudinal strain CAEL-101 led to sustained decrease in NT-proBNP levels Data presented at Ameri [Read more]